Live Breaking News & Updates on ஸ்பொந்தய்லோஆறத்ரிடிச் ஆராய்ச்சி கூட்டமைப்பு

Stay updated with breaking news from ஸ்பொந்தய்லோஆறத்ரிடிச் ஆராய்ச்சி கூட்டமைப்பு. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Targeting IL-23 Could Still Be Important for Axial SpA Treatment

Targeting IL-23 Could Still Be Important for Axial SpA Treatment
medscape.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from medscape.com Daily Mail and Mail on Sunday newspapers.

Noord Holland , Robert Landew , Louise Vanhoutte , Spondyloarthritis Research Consortium Of Canada , University Hospitals Leuven , University Hospitals Leuven Belgium , Amsterdam University Medical Center , International Congress On Spondyloarthritides , International Congress , Rik Lories , University Hospitals , Spondyloarthritis International Society Response , Spondyloarthritis Research Consortium , Ankylosing Spondylitis Disease Activity Score , Amsterdam University Medical , நூற்த் ஹாலண்ட் , ஸ்பொந்தய்லோஆறத்ரிடிச் ஆராய்ச்சி கூட்டமைப்பு ஆஃப் கனடா , ஆம்ஸ்டர்டாம் பல்கலைக்கழகம் மருத்துவ மையம் , சர்வதேச காங்கிரஸ் , பல்கலைக்கழகம் மருத்துவமனைகள் , ஸ்பொந்தய்லோஆறத்ரிடிச் ஆராய்ச்சி கூட்டமைப்பு , அங்கயலோசிங் ஸ்பான்டைலிடிஸ் நோய் நடவடிக்கை மதிப்பெண் , ஆம்ஸ்டர்டாம் பல்கலைக்கழகம் மருத்துவ ,

European Commission Approves AbbVie's RINVOQ™ (Upadacitinib) for the Treatment of Psoriatic Arthritis and Ankylosing Spondylitis


European Commission Approves AbbVie s RINVOQ™ (Upadacitinib) for the Treatment of Psoriatic Arthritis and Ankylosing Spondylitis
- RINVOQ (15 mg, once daily) is the first oral, once-daily, selective and reversible JAK inhibitor approved for three adult rheumatic indications in the European Union: rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis[1,2]
- Approval is supported by data from three pivotal clinical studies in psoriatic arthritis and ankylosing spondylitis where RINVOQ met all primary and met key secondary endpoints with a safety profile consistent with that seen in rheumatoid arthritis[2-6]
- Approvals underscore AbbVie s longstanding commitment to deliver innovative medicines for people living with rheumatic diseases ....

United Kingdom , Clin Rheumatol , Tom Hudson , Iain Mcinnes , European Commission , American College Of Rheumatology , Spondyloarthritis Research Consortium , Assessment Of Spondyloarthritis International Society , Exchange Commission , European Union , Abbvie Deutschland Gmbh Co , Versus Arthritis Professor , Spondyloarthritis International Society , Serious Adverse Events , Marketing Authorization , Psoriatic Arthritis , Ankylosing Spondylitis Disease Activity Scores , Research Consortium , Bath Ankylosing Spondylitis Functional Index , Safety Information , Allergan Aesthetics , Private Securities Litigation Reform Act , Vie Deutschland Gmbh , Accessed January , Patients With Rheumatoid , Upadacitinib Versus Placebo ,